Announced
Completed
Synopsis
Sorrento, a biopharmaceutical company, completed its acquisition of SmartPharm, a gene-encoded protein therapeutics company. Financial terms were not disclosed. "We are very encouraged by the preclinical data generated thus far by our STI-2020dna plasmid candidate against Covid-19. But beyond STI-2020dna the integration of the plasmid DNA technology with our existing antibody products has the potential to make antibody therapy much more accessible and affordable for patients, and is applicable to a multitude of indications ranging from cancer to infectious diseases," Henry Ji, Sorrento CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.